Physicians Research Group II — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$105,272	74
2024	Research	$16,676	8
2023	Research	$53,174	20
2022	Research	$14,000	4
2020	Research	$24,619	9
2019	Research	$101,311	21

Breakdown

Who paid Research payments · program years 2019–2025

Incyte Corporation $228,793 109 payments
Shire North American Group Inc $35,000 11 payments
Argenx US, Inc. $26,025 8 payments
Genentech, Inc. $16,763 3 payments
Takeda Pharmaceuticals U.S.A., Inc. $5,000 4 payments
Celgene Corporation $3,471 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $74,386 47 payments
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) $57,825 24 payments
TRuE AD2-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis $22,177 3 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa $18,876 22 payments
PH 1A B Sad Mad $16,763 3 payments
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid $14,000 4 payments
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa $11,900 2 payments
A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Pemphigus (Vulgaris or Foliaceus) (ADDRESS) $11,275 3 payments
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo $9,510 3 payments
Topical Ruxolitinib Evaluation in Vitiligo Study 2 TRuE-V2 A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo $9,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.